| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.320 | GeneticVariation | phenotype | LHGDN | Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation. | 15912114 | 2005 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | Defective thrombus formation in mice lacking coagulation factor XII. | 16009717 | 2005 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | The loss of any one of the Gas6-Rs protects mice against thromboembolism induced by collagen-epinephrine and stasis-induced thrombosis. | 16564713 | 2006 | ||||
|
0.300 | Therapeutic | phenotype | CTD_human | A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. | 17047157 | 2007 | ||||
|
0.010 | AlteredExpression | phenotype | LHGDN | In the group of patients (IS n = 103; DVT n = 92), the risk of symptomatic thromboembolism was significantly increased with elevated alpha2MG levels, with a gradual increase per mg dL(-1). | 17403113 | 2007 | ||||
|
0.410 | Biomarker | phenotype | CTD_human | Essential thrombocythemia: past and present. | 19636672 | 2009 | ||||
|
0.410 | GeneticVariation | phenotype | LHGDN | Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation. | 19174256 | 2009 | ||||
|
0.320 | Biomarker | phenotype | CTD_human | We investigated whether FVL was associated with TE risk in women with early-stage breast cancer who took adjuvant tamoxifen. | 20554945 | 2010 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage. | 20172985 | 2010 | ||||
|
0.400 | GeneticVariation | phenotype | CLINVAR | Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. | 31064749 | 2019 |